Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Revenue
€ 406,703
Profit
Caution€ -375,714
▲ 10% vs 2024
Debts
Normal€ 6.2 million
▲ 7% vs 2024
Labophar from Gent, company number BE0643723177, closed financial year 2025 with a result of € -375,714 after tax. For that financial year Labophar recorded revenue of € 406,703 and equity of € 2.5 million. Compared with financial year 2024, the result moved from € -417,897 to € -375,714. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
What happened at Labophar?
What happened at Labophar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- AQUITANIA BV stepped down as director. NBB
- CREDOPHAR BV stepped down as director. NBB
- FARMAFENDER BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 375,714. Source: NBB ↗
- AQUITANIA BV became a director. NBB
- CREDOPHAR BV became a director. NBB
- FARMAFENDER BV became a director. NBB
- New establishment in Gent. KBO
In short
From € 407,291 loss in 2021 to € 375,714 loss in 2025.
Paid € 173,593 in corporate taxes since 2021.
A new publication or filing at Labophar? We notify you, reason included.
Follow LabopharNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by CREDOPHAR (100%). It owns 100% of DGPharma and 100% of b+pharma Belgium itself.
Directors
According to the 2025 annual accounts
Director · represented by ANJA IMSCHOOT
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium +6 more
since 2022 · until 2028
since 2022 · until 2028
Managing director · represented by BRAM VAN PETEGHEM
Also active at: b+pharma Belgium, DGPharma
since 2022 · until 2028
Shareholders
100%
Participations
100%
100%
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
+15 more
Details
- Company number
- 0643.723.177
- VAT number
- BE 0643.723.177
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- Labophar
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 30 November 2015
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Handel in eigen onroerend goed
Detailhandel in farmaceutische producten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Groothandel in farmaceutische en medische artikelen
Overige technische testen en toetsen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied